298 related articles for article (PubMed ID: 15254225)
1. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway.
Yaguchi H; Ohkura N; Takahashi M; Nagamura Y; Kitabayashi I; Tsukada T
Mol Cell Biol; 2004 Aug; 24(15):6569-80. PubMed ID: 15254225
[TBL] [Abstract][Full Text] [Related]
2. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms.
Shimazu S; Nagamura Y; Yaguchi H; Ohkura N; Tsukada T
Cancer Sci; 2011 Nov; 102(11):2097-102. PubMed ID: 21819486
[TBL] [Abstract][Full Text] [Related]
3. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA.
Canaff L; Vanbellinghen JF; Kanazawa I; Kwak H; Garfield N; Vautour L; Hendy GN
J Clin Endocrinol Metab; 2012 Feb; 97(2):E282-91. PubMed ID: 22090276
[TBL] [Abstract][Full Text] [Related]
4. Application of an intracellular stability test of a novel missense menin mutant to the diagnosis of multiple endocrine neoplasia type 1.
Nagamura Y; Yamazaki M; Shimazu S; Tsukada T; Sakurai A
Endocr J; 2012; 59(12):1093-8. PubMed ID: 22878668
[TBL] [Abstract][Full Text] [Related]
5. Wild-type menin is rapidly degraded via the ubiquitin-proteasome pathway in a rat insulinoma cell line.
Jiang Z; Wan S; Xing B
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652443
[TBL] [Abstract][Full Text] [Related]
6. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells.
Bazzi W; Renon M; Vercherat C; Hamze Z; Lacheretz-Bernigaud A; Wang H; Blanc M; Roche C; Calender A; Chayvialle JA; Scoazec JY; Cordier-Bussat M
Gastroenterology; 2008 Nov; 135(5):1698-1709.e2. PubMed ID: 18775714
[TBL] [Abstract][Full Text] [Related]
7. Multiple endocrine neoplasia type 1: a chromatin writer's block.
Dreijerink KM; Lips CJ; Timmers HT
J Intern Med; 2009 Jul; 266(1):53-9. PubMed ID: 19522825
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.
Dreijerink KMA; Ozyerli-Goknar E; Koidl S; van der Lelij EJ; van den Heuvel P; Kooijman JJ; Biniossek ML; Rodenburg KW; Nizamuddin S; Timmers HTM
Epigenetics Chromatin; 2022 Aug; 15(1):29. PubMed ID: 35941657
[TBL] [Abstract][Full Text] [Related]
9. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Tsai YC; Fishman PS; Thakor NV; Oyler GA
J Biol Chem; 2003 Jun; 278(24):22044-55. PubMed ID: 12676955
[TBL] [Abstract][Full Text] [Related]
10. Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype.
Perakakis N; Flohr F; Kayser G; Thomusch O; Parsons L; Billmann F; von Dobschuetz E; Rondot S; Seufert J; Laubner K
Hormones (Athens); 2016; 15(1):113-7. PubMed ID: 26732163
[TBL] [Abstract][Full Text] [Related]
11. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases.
Corbo V; Dalai I; Scardoni M; Barbi S; Beghelli S; Bersani S; Albarello L; Doglioni C; Schott C; Capelli P; Chilosi M; Boninsegna L; Becker KF; Falconi M; Scarpa A
Endocr Relat Cancer; 2010 Sep; 17(3):771-83. PubMed ID: 20566584
[TBL] [Abstract][Full Text] [Related]
12. Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients.
Luzi E; Marini F; Tognarini I; Carbonell Sala S; Galli G; Falchetti A; Brandi ML
Cancer Gene Ther; 2010 Nov; 17(11):814-25. PubMed ID: 20706287
[TBL] [Abstract][Full Text] [Related]
13. MEN1 gene and its mutations: basic and clinical implications.
Tsukada T; Nagamura Y; Ohkura N
Cancer Sci; 2009 Feb; 100(2):209-15. PubMed ID: 19068082
[TBL] [Abstract][Full Text] [Related]
14. Metabolic expressivity of human genetic variants: NMR metabotyping of MEN1 pathogenic mutants.
Blaise BJ; Lopez C; Vercherat C; Lacheretz-Bernigaud A; Bayet-Robert M; Rezig L; Scoazec JY; Calender A; Emsley L; Elena-Herrmann B; Cordier-Bussat M
J Pharm Biomed Anal; 2014 May; 93():118-24. PubMed ID: 24183932
[TBL] [Abstract][Full Text] [Related]
15. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene.
Sukhodolets KE; Hickman AB; Agarwal SK; Sukhodolets MV; Obungu VH; Novotny EA; Crabtree JS; Chandrasekharappa SC; Collins FS; Spiegel AM; Burns AL; Marx SJ
Mol Cell Biol; 2003 Jan; 23(2):493-509. PubMed ID: 12509449
[TBL] [Abstract][Full Text] [Related]
16. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.
Chen G; A J; Wang M; Farley S; Lee LY; Lee LC; Sawicki MP
Mol Cancer Res; 2008 Dec; 6(12):1894-907. PubMed ID: 19074834
[TBL] [Abstract][Full Text] [Related]
17. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23.
Ohkura N; Kishi M; Tsukada T; Yamaguchi K
Biochem Biophys Res Commun; 2001 Apr; 282(5):1206-10. PubMed ID: 11302744
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy.
Abu-Baker A; Messaed C; Laganiere J; Gaspar C; Brais B; Rouleau GA
Hum Mol Genet; 2003 Oct; 12(20):2609-23. PubMed ID: 12944420
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.
Dreijerink KM; Höppener JW; Timmers HM; Lips CJ
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):562-70. PubMed ID: 17024155
[TBL] [Abstract][Full Text] [Related]
20. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
